(Q79134557)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

High time for low-dose prospective clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

High time for low‐dose prospective clinical trials (English)

1 reference

19 March 2024

1 reference

19 March 2024

author name string

Robert S. DiPaola

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534869

19 March 2024

Henry J. Durivage

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534869

19 March 2024

Barton A. Kamen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14534869

19 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14534869

19 March 2024

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

15 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14534869

full work available at URL

19 March 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.11709

1 reference

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.11709

19 March 2024

1 reference

19 March 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

1559-1561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Why not start with thalidomide?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Could less be more? Low-dose chemotherapy goes on trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

High-time chemotherapy or high time for low dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Back to the basics: the importance of concentration x time in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

The dangers of ad hoc protocols

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Reducing patient eligibility criteria in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Viewpoints and concerns of a clinical trial participant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11709

7 January 2021

Identifiers

DOI

10.1002/CNCR.11709

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14534869%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference